A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)

Inclusion Criteria: * Histologic documentation of epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer * Safety run-in only: PROC. Patients may have received more than 1 prior systemic treatment regimen in the PROC setting. * Part A and Part B only: Patients with PROC who have received 1 to 3 anticancer lines of therapy overall, including at least 1 line of therapy containing bevacizumab or biosimilar. * Adjuvant ± neoadjuvant are considered 1 line of therapy. * Patients may have received a PARP inhibitor or an immuno-oncology (IO) agent; any of these regimens are to be considered a line of therapy for the purposes of this study if not used as maintenance therapy. * Maintenance therapy (including bevacizumab, PARP inhibitors and IOs) will be considered part of the preceding line of therapy and not to be counted as a new line of therapy. * Any chemotherapy regimen change due to toxicity in the absence of disease progression is considered as part of the same line of therapy. * Hormonal therapy will be not be counted towards the lines of therapy. * Measurable disease according to RECIST v1.1 as assessed by the investigator * An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 * Life expectancy of at least 3 months * Able to provide fresh or archival tissue for biomarker analysis Exclusion Criteria: * Primary platinum-refractory disease, defined as disease progression within 2 months of completion of first line p…